GlassScriptPhysician profile
Peter T Brennan
NPI 1780655118
$2,293.04
in general payments reported to CMS, 2019-2025
20 companies · $68.10 in 2025
The $68.10 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $293 · 2021: $100 · 2022: $308 · 2023: $496 · 2024: $552 · 2025: $68.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.89 |
| Education | $115.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.18 | 2019-2024 | Rinvoq, Skyrizi, Viberzi |
| Janssen Biotech, INC. | $472.07 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $232.18 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.04 | 2019-2024 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $143.82 | 2020-2023 | Dupixent |
| Madrigal Pharmaceuticals | $111.54 | 2024 | Resmetirom, Rezdiffra |
| Sun Pharmaceutical Industries INC. | $106.55 | 2019-2025 | Cequa |
| Braintree Laboratories, INC. | $75.70 | 2019-2023 | Suflave |
| Ferring Pharmaceuticals INC. | $50.83 | 2019-2024 | Clenpiq |
| Celgene Corporation | $35.38 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $31.82 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $26.57 | 2024 | Givlaari |
| Allergan, INC. | $24.41 | 2019 | |
| Ardelyx, INC. | $23.63 | 2024 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $15.94 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $14.61 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.60 | 2022 | |
| Aimmune Therapeutics, INC. | $14.02 | 2024 | |
| Merck Sharp & Dohme LLC | $12.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.